Vaccine for falciparum malaria

Patent metadata

Field	Value
Publication number	US-10960065-B2
Application number	US-201916283472-A
Country	US
Kind code	B2
Filing date	Feb 22, 2019
Priority date	Dec 2, 2011
Publication date	Mar 30, 2021
Grant date	Mar 30, 2021

Abstract

The invention provides compositions and methods for preventing or reducing the severity of malaria.

First claim

The invention claimed is:

1. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PfGARP polypeptide antigen comprising the amino acid sequence of PfGARP (SEQ ID NO: 27) or a fragment thereof, said fragment thereof comprising the amino acid sequence of PfGARP (SEQ ID NO: 26), further comprising an adjuvant.

2. The vaccine of claim 1 , wherein said composition comprises a purified polypeptide comprising the amino acid sequence of SEQ ID NO: 26.

3. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising the amino acid sequence of CDPK5 (SEQ ID NO: 47), SERA5 (SEQ ID NO: 70, 72), PfSUB1 (SEQ ID NO: 74), or PfPKG (SEQ ID NO: 76).

4. The vaccine of claim 1 , wherein said composition comprises said purified PfGARP polypeptide antigen comprising the amino acid sequence of PfGARP (SEQ ID NO: 27) or a fragment thereof, said fragment thereof comprising the amino acid sequence of PfGARP (SEQ ID NO: 26) and wherein said composition elicits an antibody immune response against PfGARP.

5. The vaccine of claim 1 , wherein said composition further comprises a purified anti-PfGARP antibody or antigen binding fragment thereof.

6. The vaccine of claim 5 , wherein said antibody binds to an antigen comprising a polypeptide having at least 70% identity with an amino acid sequence of SEQ ID NO: 26 or 27 or a fragment thereof.

7. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 14, 18, 22, 30, 34, 38, 42, 46, 66 and 72.

8. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 11, 15, 19, 22, 31, 35, 39, 43, 47, 67, 70, 74, and 76 or fragments thereof.

9. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 10, 11, 14, 15, 18, 19, 22, 23, 30, 31, 34, 35, 38, 39, 42, 43, 46, 47, 66, 67, 70, 72, 74, and 76 or an immunogenic fragment thereof.

10. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising an amino acid sequence of 6, 7, 10, 11, 14, 15, 18, 19, 22, 23, 30, 31, 34, 35, 38, 39, 42, 43, 46, 47, 66, 67, 70, 72, 74, and/or 76.

11. The vaccine of claim 1 , wherein said antigen comprising a polypeptide of SEQ ID NO: 27 or SEQ ID NO: 26 is encoded by a polynucleotide having at least 70% identity with the nucleic acid sequence of SEQ ID NO: 25.

12. The vaccine of claim 11 , wherein said polypeptide is encoded by a polynucleotide having the nucleic acid sequence of SEQ ID NO: 25.

13. An isolated peptide comprising a peptide having at least 95% to 99% identity with the sequence of SEQ ID NO: 27 or a fragment thereof, wherein said peptide or fragment thereof elicits an anti-PfGARP antibody response against P. falciparum malaria, further comprising an adjuvant.

14. The peptide of claim 13 , wherein said peptide comprises SEQ ID NO: 27 or a fragment thereof, wherein said fragment comprises the amino acid sequence of SEQ ID NO: 26.

15. The vaccine of claim 1 , wherein the composition further comprises a purified polypeptide comprising the amino acid sequence of PfSEP1 (SEQ ID NO:3) or a fragment thereof, said fragment thereof comprising the amino acid sequence of PfSEP1A (SEQ ID NO:2).

Assignees

• Rhode Island Hospital
• Seattle Biomedical Res Institute
• Seattle Childrens Hospital

Inventors

• Kurtis Jonathan
• Nixon Christian Parcher
• Raj Dipak Kumar
• Friedman Jennifer Frances
• Fried Michal
• Duffy Patrick Emmet

Classifications

• A61P33/00

  Antiparasitic agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07K16/205

  Plasmodium · CPC title

• C07K16/44

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title